Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.
about
SHP family protein tyrosine phosphatases adopt canonical active-site conformations in the apo and phosphate-bound statesAndrographolide induces vascular smooth muscle cell apoptosis through a SHP-1-PP2A-p38MAPK-p53 cascade.Interferons and their stimulated genes in the tumor microenvironmentPhosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.Molecular insights for optimizing T cell receptor specificity against cancer.Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.SHP-1: the next checkpoint target for cancer immunotherapy?Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders.Modulation of VEGF receptor 2 signaling by protein phosphatases.Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.Shp1 function in myeloid cells.Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticlesDevelopment of a screening strategy for new modulators of T cell receptor signaling and T cell activation.
P2860
Q27684212-A42C2B89-E266-4F67-A607-1DFEA13A3C36Q30583338-72DC8333-3ED5-49CC-936A-B70745D8FFFBQ33988567-BAD4442A-03FA-4426-8C71-F0A0E798C7C8Q35764349-15D365F5-E5BE-4B09-88B4-1C3985DABA6FQ37263972-DFA65FE7-3FBD-43AA-A140-674FBC182085Q37855897-D4BB0BC7-6936-45A0-A10C-ECA7ACEEFD7AQ38117139-9B930781-1313-4DAC-B9E3-394906AA6920Q38261370-8645B7B2-0021-4474-A9BC-E6ADBB42C465Q38805738-665EA098-FA96-413B-B313-88F4062E1605Q38842536-C10EA9C0-E1B5-4286-A12A-04D22CAC287AQ39020269-E954E71B-7FF3-45DE-A6E7-1FF7C287D992Q39088131-046A3E60-0C14-4037-82FF-59D95242F3AEQ39367824-21C8A508-59E7-4AF1-8BE0-38ED480D7784Q42234959-64129B8A-5A5C-490A-B612-D030212B0568Q55646587-E6790A25-BF7F-478E-8700-790EC876E7D4
P2860
Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@ast
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@en
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@nl
type
label
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@ast
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@en
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@nl
prefLabel
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@ast
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@en
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@nl
P2093
P2860
P356
P1476
Novel SHP-1 inhibitors tyrosin ...... ties as tolerated oral agents.
@en
P2093
Daniel J Lindner
Ernest Borden
Mingli Cao
Suman Kundu
Zhizhaung Joe Zhao
P2860
P304
P356
10.4049/JIMMUNOL.0903562
P407
P577
2010-04-26T00:00:00Z